BMP-2 differentially modulates FGF-2 isoform effects in osteoblasts from newborn transgenic mice

Endocrinology

Volumn 154, Issue 8, 2013, Pages 2723-2733

  Sabbieti, Maria Giovanna ^a   Agas, Dimitrios ^a   Marchetti, Luigi ^a   Coffin, J Douglas ^b   Xiao, Liping ^c   Hurley, Marja M ^c  

^a UNIVERSITY OF CAMERINO   (Italy)

^b UNIVERSITY OF MONTANA   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BONE MORPHOGENETIC PROTEIN 2; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2;

ANIMAL CELL; ARTICLE; BONE MINERALIZATION; CELL CULTURE; CONTROLLED STUDY; GENOTYPE; INTRACELLULAR SIGNALING; MOTHER; MOUSE; NEWBORN; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; WESTERN BLOTTING;

ALKALINE PHOSPHATASE; ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; BONE MORPHOGENETIC PROTEIN 2; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 1 SUBUNIT; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MALE; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; OSTEOBLASTS; PHOSPHORYLATION; PROTEIN ISOFORMS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RNA INTERFERENCE; SKULL; SMAD PROTEINS; TRANSCRIPTION FACTORS;

EID: 84880683813     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1025     Document Type: Article

References (49)

1. Yamaguchi A. Regulation of differentiation pathway of skeletal mesenchymal cells in cell lines by transforming growth factor-β superfamily. Semin Cell Biol. 1995;6:165-173.
2. Rosen V, Wozney JM. Bone morphogenetic proteins. In: Belizikian J, Raisz LG, Rodan G, eds. Principles of Bone Biology. 2nd ed. San Diego: Academic Press; 2002:919-928.
3. Miyazono K, Maeda S, Imamura T. BMP receptor signaling: Trandoi scriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev. 2005;16:251-263.
4. Papachroni KK, Karatzas DN, Papavassiliou KA, Basdra EK, Papavassiliou AG. Mechanotransduction in osteoblast regulation and bone disease. Trends Mol Med. 2009;15:208-216.
5. Hanai J, Chen LF, Kanno T, et al Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Cα promoter. Biol Chem. 1999;274: 31577-31582.
6. Javed A, Barnes GL, Jasanya BO, et al. Runt homology domain transcription factors (Runx, Cbfa, and AML) mediate repression of the bone sialoprotein promoter: Evidence for promoter context dependent activity of Cbfa proteins. Mol Cell Biol. 2001;21:2891-2905.
7. Otto F, Thornell AP, Crompton T, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell. 1997;89:765-771.
8. Otto F, Kanegane H, Mundlos S. Mutations in the RUNX2 gene in patients with cleidocranial dysplasia. Hum Mutat. 2002;19:209-216.
9. Yoshida T, Kanegane H, Yoshida T, et al. Functional analysis of RUNX2mutations in Japanese patients with cleidocranial dysplasia demonstrates novel genotype-phenotype correlations. Am J Hum Genet. 2002;71:724-738.
10. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997;89:755-764.
11. Karsenty G. Minireview: Transcriptional control of osteoblast differentiation. Endocrinology. 2001;142:2731-2733.
12. Stein GS, Lian JB, Stein J, Van Wijnen AJ, Montecino M. Transcriptional control of osteoblast growth and differentiation. Physiol Rev. 1996;76:593-629.
13. Yang X, Karsenty G. Transcription factors in bone: Developmental and pathological aspects. Trends Mol Med. 2002;8:340-345.
14. Nakashima K, Zhou X, Kunkel G, et al. The novel zinc fingercontaining transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 2002;108:17-29.
15. Hurley MM, Marie P, Forkiewicz R. Fibroblasts growth factor and fibroblasts growth factor receptor families. In: Bilezikian JP, Raisz LG, Rodan G, eds. Principles of Bone Biology. San Diego: Academic Press; 2002:825-852.
16. Montero A, Okada Y, Tomita M, et al. Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J Clin Invest. 2000;105:1085-1093.
17. Abraham JA, Whang JL, Tumolo A, et al. Human basic fibroblast growth factor: Nucleotide sequence and genomic organization. EMBO J. 1986;5:2523-2528.
18. Florkiewicz RZ, Sommer A. Human basic fibroblast growth factor gene encodes four polypeptides: Three initiate translation from non-AUG codons. Proc Natl Acad Sci USA. 1989;86:3981-3987.
19. Prats H, Kaghad M, Prats AC, et al. High molecular mass forms of basic fibroblast growth factor are initiated by alternative CUG codons. Proc Natl Acad Sci USA. 1989;86:1836-1840.
20. Powell PP, Klagsbrun M. Three forms of rat basic fibroblast growth factor are made from a single mRNA and localize to the nucleus. J Cell Physiol. 1991;148:202-210.
21. Stachowiak M, Moffett J, Joy A, Puchacz E, Florkiewicz R, Stachowiak E. Regulation of bFGF gene expression and subcellular distribution of bFGF protein in adrenal medullary cells. J Cell Biol. 1994;127:203-222.
22. Touriol C, Bornes S, Bonnal S, Audigier S, Prats H, PratsAC,Vagner S. Generation of protein isoform diversity by alternative initiation of translation at non-AUG codons. Biol Cell. 2003;95:169-178.
23. Sabbieti MG, Marchetti L, Abreu C, et al. Prostaglandins regulate the expression of fibroblast growth factor-2 in bone. Endocrinology. 1999;140:434-444.
24. Sobue T, Naganawa T, Xiao L, et al. Over-expression of fibroblast growth factor-2 causes defective bone mineralization and osteopenia in transgenic mice. J Cell Biochem. 2005;95:83-94.
25. Xiao L, Liu P, Sobue T, Lichtler A, Coffin JD, Hurley MM. Effect of overexpressing fibroblast growth factor 2 protein isoforms in osteoblastic ROS 17/2.8 cells. J Cell Biochem 2003;89:1291-1301.
26. SabbietiMG,Agas D, Materazzi S, et al. Prostaglandin F2α involves heparin sulphate sugar chains and FGFRs to modulate osteoblast growth and differentiation. J Cell Physiol. 2008;217:48-59.
27. Agas D, Marchetti L, Menghi G, et al. Anti-apoptotic Bcl-2 enhancing requires FGF-2/FGF receptor 1 binding in mouse osteoblasts. J Cell Physiol. 2008;214:145-152.
28. Sabbieti MG, Agas D, Marchetti L, et al. Signaling pathways implicated in PGF2α effects on Fgf2+/+ and Fgf2-/-osteoblasts. J Cell Physiol. 2010;224:465-474.
29. Sabbieti MG, Agas D, Xiao L, et al. Endogenous FGF-2 is critically important in PTH anabolic effects on bone. J Cell Physiol. 2009; 219:143-151.
30. Naganawa T, Xiao L, Coffin JD, et al. Reduced expression and function of bone morphogenetic protein-2 in bones of Fgf2 null mice. J Cell Biochem. 2008;103:1975-1988.
31. Naganawa T, Xiao L, Abogunde E, et al. In vivo and in vitro comparison of the effects of FGF-2 null and haplo-insufficiency on bone formation in mice. Biochem Biophys ResCommun. 2006;339:490-498.
32. Xiao L, Liu P, Li X, et al. Exported 18-kDa isoform of fibroblast growth factor-2 is a critical determinant of bone mass in mice. J Biol Chem. 2009;284:3170-3182.
33. Kuo P, Hsu Y, Chang CH, Chang JK. Ostholemediated cell differentiation through bone morphogenetic protein-2/p38 and extracellular signal-regulated kinase pathway in human osteoblast cells. J Pharm Exp Ther. 2005;314:1290-1299.
34. Mukherjee A. Rotwein P. Akt promotes BMP-2-mediated osteoblast differentiation and bone development. J Cell Sci. 2009;122:716-726.
35. Xiao L, Naganawa T, Lorenzo J, Carpenter TO, Coffin JD, Hurley MM. Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO. J Biol Chem. 2010;285:2834-2846.
36. Wang X, Goh CH, Li B. p38 mitogen-activated protein kinase regulates osteoblast differentiation through osterix. Endocrinology. 2007;148:1629-1637.
37. Franceschi RT, Xiao G, Jiang D, Gopalakrishnan R, Yang S, Reith E. Multiple signaling pathways converge on the Cbfa1/Runx2 transcription factor to regulate osteoblast differentiation. Connect Tissue Res 2003;44(suppl 1):109-116.
38. Kanno T, Takahashi T, Tsujisawa T, Ariyoshi W, Nishihara T. Mechanical stress-mediated Runx2 activation is dependent on Ras/ERK1/2 MAPK signaling in osteoblasts. J Cell Biochem. 2007;101: 1266-1277.
39. Xiao G, Gopalakrishnan R, Jiang D, Reith E, Benson MD, Franceschi RT. Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells. J Bone Miner Res. 2002;17:101-110.
40. Park OJ, Kim HJ, Woo KM, Baek JH, Ryoo HM. FGF2-activated ERK mitogen-activated protein kinase enhances Runx2 acetylation and stabilization. J Biol Chem. 2010;285:3568-3574.
41. Higuchi C, Myoui A, Hashimoto N, et al. Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix. J Bone Miner Res 2002; 17:1785-1794.
42. Chow JY, Quach KT, Cabrera BL, Cabral JA, Beck SE, Carethers JM. RAS/ERK modulates TGF?-regulated PTEN expression in human pancreatic adenocarcinoma cells. Carcinogenesis. 2007; 28: 2321-2327.
43. Eivers E, Fuentealba LC, De Robertis EM. Integrating positional information at the levels of Smad 1/5/8. Curr Opin Genet Dev. 2008;18:304-310.
44. Raucci A, Bellosta P, Grassi R, Basilico C, Mansukhani A. Osteoblast proliferation or differentiation is regulated by relative strengths of opposing signaling pathways. J Cell Physiol. 2008;215: 442-451.
45. Agas D, Sabbieti MG, Marchetti L, Xiao L, Hurley MM. FGF-2 enhances Runx-2/Smads nuclear localization in BMP-2 canonical signaling in osteoblasts. [published online April 5, 2013] J Cell Physiol. doi: 10.1002/jcp. 24382.
46. Lee MH, Kwon TG, Park HS, Wozney JM, Ryoo HM. BMP-2-induced Osterix expression is mediated by Dlx5 but is independent of Runx2. Biochem Biophys Res Commun. 2003;309:689-694.
47. Tanimoto Y, Yokozeki M, Hiura K, et al. A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome. J Biol Chem. 2004; 279:45926-45934.
48. Miraoui H, Oudina K, Petite H, Tanimoto Y, Moriyama K, Marie PJ. Fibroblast growth factor receptor 2 promotes osteogenic differentiation in mesenchymal cells via ERK1/2 and protein kinase C signaling. J Biol Chem. 2009;284:4897-4904.
49. Kuhn LT, Ou G, Charles L, Hurley MM, Rodner CM, Gronowicz G. Fibroblast growth factor-2 and bone morphogenetic protein-2 have a synergistic stimulatory effect on bone formation in cell cultures from elderly mouse and human bone. [published online March 26, 2013] J Gerontol A Biol Sci Med Sci. doi:10.1093/gerona/glt018.